201 related articles for article (PubMed ID: 17116220)
21. [The rational immunotherapy with intravenous immunoglobulin in neurologic diseases].
Korsak J
Pol Merkur Lekarski; 2011 Jun; 30(180):430-4. PubMed ID: 21751554
[TBL] [Abstract][Full Text] [Related]
22. Immune mediated neuropathies--an update on therapeutic strategies.
Czaplinski A; Steck AJ
J Neurol; 2004 Feb; 251(2):127-37. PubMed ID: 14991345
[TBL] [Abstract][Full Text] [Related]
23. Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.
Krakauer M; Sorensen PS; Khademi M; Olsson T; Sellebjerg F
Scand J Immunol; 2006 Aug; 64(2):155-63. PubMed ID: 16867161
[TBL] [Abstract][Full Text] [Related]
24. Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris.
Teraki Y; Miyake A; Takebayashi R; Shiohara T
Clin Exp Dermatol; 2004 Nov; 29(6):658-63. PubMed ID: 15550147
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of different brands of intravenous immunoglobulin in the maintenance treatment of chronic immune-mediated neuropathies.
Gallia F; Balducci C; Nobile-Orazio E
J Peripher Nerv Syst; 2016 Jun; 21(2):82-4. PubMed ID: 26817673
[TBL] [Abstract][Full Text] [Related]
26. Chemokine and chemokine receptor analysis reveals elevated interferon-inducible protein-10 (IP)-10/CXCL10 levels and increased number of CCR5+ and CXCR3+ CD4 T cells in synovial fluid of patients with enthesitis-related arthritis (ERA).
Aggarwal A; Agarwal S; Misra R
Clin Exp Immunol; 2007 Jun; 148(3):515-9. PubMed ID: 17374135
[TBL] [Abstract][Full Text] [Related]
27. Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients.
Gomes JA; Bahia-Oliveira LM; Rocha MO; Busek SC; Teixeira MM; Silva JS; Correa-Oliveira R
Infect Immun; 2005 Dec; 73(12):7960-6. PubMed ID: 16299288
[TBL] [Abstract][Full Text] [Related]
28. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis.
Haringman JJ; Smeets TJ; Reinders-Blankert P; Tak PP
Ann Rheum Dis; 2006 Mar; 65(3):294-300. PubMed ID: 16107514
[TBL] [Abstract][Full Text] [Related]
29. Chemokine receptor expression in peripheral blood monocytes from patients with neovascular age-related macular degeneration.
Grunin M; Burstyn-Cohen T; Hagbi-Levi S; Peled A; Chowers I
Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5292-300. PubMed ID: 22789920
[TBL] [Abstract][Full Text] [Related]
30. Expression pattern of chemokine receptors and chemokine release in inflammatory erythroderma and Sézary syndrome.
Fierro MT; Comessatti A; Quaglino P; Ortoncelli M; Osella Abate S; Ponti R; Novelli M; Bernengo MG
Dermatology; 2006; 213(4):284-92. PubMed ID: 17135733
[TBL] [Abstract][Full Text] [Related]
31. Intravenous immunoglobulin G modulates peripheral blood Th17 and Foxp3(+) regulatory T cells in pregnant women with recurrent pregnancy loss.
Kim DJ; Lee SK; Kim JY; Na BJ; Hur SE; Lee M; Kwak-Kim J
Am J Reprod Immunol; 2014 May; 71(5):441-50. PubMed ID: 24645850
[TBL] [Abstract][Full Text] [Related]
32. IVIg-induced plasmablasts in patients with Guillain-Barré syndrome.
Brem MD; Jacobs BC; van Rijs W; Fokkink WJR; Tio-Gillen AP; Walgaard C; van Doorn PA; IJspeert H; van der Burg M; Huizinga R
Ann Clin Transl Neurol; 2019 Jan; 6(1):129-143. PubMed ID: 30656191
[TBL] [Abstract][Full Text] [Related]
33. Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy.
Maddur MS; Stephen-Victor E; Das M; Prakhar P; Sharma VK; Singh V; Rabin M; Trinath J; Balaji KN; Bolgert F; Vallat JM; Magy L; Kaveri SV; Bayry J
J Neuroinflammation; 2017 Mar; 14(1):58. PubMed ID: 28320438
[TBL] [Abstract][Full Text] [Related]
34. Changes in lymphocyte subsets in patients with Guillain-Barré syndrome treated with immunoglobulin.
Hou HQ; Miao J; Feng XD; Han M; Song XJ; Guo L
BMC Neurol; 2014 Oct; 14():202. PubMed ID: 25315010
[TBL] [Abstract][Full Text] [Related]
35. Intravenous immunoglobulin in autoimmune neuromuscular diseases.
Dalakas MC
JAMA; 2004 May; 291(19):2367-75. PubMed ID: 15150209
[TBL] [Abstract][Full Text] [Related]
36. [Diagnosis and management of immune-mediated neuropathies].
Hsieh ST
Acta Neurol Taiwan; 2004 Mar; 13(1):39-45. PubMed ID: 15315301
[TBL] [Abstract][Full Text] [Related]
37. Nickel-responding T cells are CD4+ CLA+ CD45RO+ and express chemokine receptors CXCR3, CCR4 and CCR10.
Moed H; Boorsma DM; Stoof TJ; von Blomberg BM; Bruynzeel DP; Scheper RJ; Gibbs S; Rustemeyer T
Br J Dermatol; 2004 Jul; 151(1):32-41. PubMed ID: 15270870
[TBL] [Abstract][Full Text] [Related]
38. Intravenous immunoglobulin treatment on anti-GM1 antibodies associated neuropathies inhibits cholera toxin and galectin-1 binding to ganglioside GM1.
Peng W
Immunol Lett; 2012 Apr; 143(2):146-51. PubMed ID: 22289946
[TBL] [Abstract][Full Text] [Related]
39. Circulating subsets and CD4(+)CD25(+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy.
Sanvito L; Makowska A; Gregson N; Nemni R; Hughes RA
Autoimmunity; 2009; 42(8):667-77. PubMed ID: 19886739
[TBL] [Abstract][Full Text] [Related]
40. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors.
Aeberli D; Seitz M; Jüni P; Villiger PM
Rheumatology (Oxford); 2005 Feb; 44(2):172-5. PubMed ID: 15509629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
